Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 69.00 | 138.25 | 0.4991 | -0.3942 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 174.00 | 138.25 | 1.2586 | 1.9695 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 156.25 | 92.36 | 72.00 | 138.25 | 0.5208 | -0.3482 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 121.00 | 138.25 | 0.8752 | 0.5906 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 90.00 | 138.25 | 0.6510 | -0.0436 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 126.00 | 138.25 | 0.9114 | 0.7052 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 156.25 | 92.36 | 103.00 | 138.25 | 0.7450 | 0.2060 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 93.00 | 138.25 | 0.6727 | 0.0119 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 303.00 | 313.25 | 0.9673 | 0.8993 | |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 312.50 | 200.50 | 337.00 | 313.25 | 1.0758 | 1.2405 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 205.00 | 313.25 | 0.6544 | 0.0351 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 312.50 | 200.50 | 359.00 | 313.25 | 1.1460 | 1.4717 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 312.50 | 200.50 | 397.00 | 313.25 | 1.2674 | 1.8899 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 415.00 | 313.25 | 1.3248 | 2.0960 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 312.50 | 200.50 | 339.00 | 313.25 | 1.0822 | 1.2611 |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 312.50 | 200.50 | 281.00 | 313.25 | 0.8971 | 0.6894 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 360.00 | 313.25 | 1.1492 | 1.4824 | |
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 312.50 | 200.50 | 458.00 | 313.25 | 1.4621 | 2.6084 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 415.00 | 313.25 | 1.3248 | 2.0960 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 249.00 | 313.25 | 0.7949 | 0.4001 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 312.50 | 200.50 | 384.00 | 313.25 | 1.2259 | 1.7442 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 373.00 | 313.25 | 1.1907 | 1.6231 | |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 312.50 | 200.50 | 389.00 | 313.25 | 1.2418 | 1.7999 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 312.50 | 200.50 | 181.00 | 313.25 | 0.5778 | -0.1470 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 312.50 | 200.50 | 406.00 | 313.25 | 1.2961 | 1.9923 |